Search

Author/Creator Reck, M

2. 127TiP PROPEL: A phase I/II trial of bempegaldesleukin (NKTR-214) in combination with pembrolizumab (pembro) in patients (pts) with advanced solid tumours. (15th December 2019)

Authors:
Reck, M; Cappuzzo, F; Rodriguez-Abreu, D; Cho, D C; Schwarz, J K; Riese, M J; Gupta, A; Chan, T; Saab, R; Singel, S; Lin, W; Tagliaferri, M; Spigel, D R
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 11
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 1386PDIMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC. (23rd October 2018)

Authors:
Reck, M; Wehler, T; Orlandi, F; Nogami, N; Barone, C; Moro-Sibilot, D; Shtivelband, M; González Larriba, J L; Rothenstein, J; Frueh, M; Shankar, G; Lee, A; Deng, Y; Patel, H; Kelsch, C; Lin, W; Socinski, M A
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 1449PEfficacy of afatinib in the clinical practice: First results of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC in Germany. (23rd October 2018)

Authors:
Brueckl, W M; Laack, E; Reck, M; Griesinger, F; Schäfer, H; Kortsik, C; Gaska, T; Rawluk, J; Krüger, S; Kokowski, K; Budweiser, S; Schueler, A; Kiessling, S
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 1464PKEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?. (23rd October 2018)

Authors:
Rodriguez Abreu, D; Garassino, M C; Esteban, E; Speranza, G; Felip, E; Domine, M; Hochmair, M J; Powell, S F; Cheng, S Y-S; Bischoff, H; Peled, N; Hui, R; Reck, M; Garon, E B; Boyer, M; Grossi, F; Jennens, R; Yang, J; Pietanza, M C; Gadgeel, S M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. 533TiPCANOPY-2: A phase III, placebo-controlled study of canakinumab with or without docetaxel in patients (pts) with NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (Ctx). (24th November 2019)

Authors:
Lim, D; Goto, Y; Cho, B C; Kaneda, H; Kang, J-H; Kim, S-W; Chiu, C-H; Yang, J C-H; Su, W-C; Obyrne, K; Papadimitrakopoulou, V; Reck, M; Malet, I; Mookerjee, B; Zewen, Z; Rodriguez, L Paz-Ares
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗